Be part of the knowledge.™

Oncology and Hematology

838

LikeLikedUnlike

16-30 of 282

Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
MinuteCE®
Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
- Komal Jhaveri, MD, FACP
  Peer
1.00 program credits
The Future of Oral SERDs: Combination Strategies
MinuteCE®
The Future of Oral SERDs: Combination Strategies
- Komal Jhaveri, MD, FACP
  Peer
1.00 program credits
Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC 
MinuteCE®
Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC 
- Giuseppe Curigliano, MD, PhD
  Peer
- Komal Jhaveri, MD, FACP
  Peer
1.00 program credits
Routes Reconsidered: A Case-Based Debate in SERD Selection
MinuteCE®
Routes Reconsidered: A Case-Based Debate in SERD Selection
- Giuseppe Curigliano, MD, PhD
  Peer
- Komal Jhaveri, MD, FACP
  Peer
1.00 program credits
Spotlight on Europe: Adapting the Evidence
MinuteCE®
Spotlight on Europe: Adapting the Evidence
- Giuseppe Curigliano, MD, PhD
  Peer
1.00 program credits
Spotlight on Latin America: Closing the Gap
MinuteCE®
Spotlight on Latin America: Closing the Gap
- Cynthia Villarreal-Garza, MD, DSc
  Peer
1.00 program credits
advertisement
Spotlight on Asia-Pacific: Practice Beyond Borders
MinuteCE®
Spotlight on Asia-Pacific: Practice Beyond Borders
- Hiraji Iwata, MD, PhD
  Peer
1.00 program credits
Breaking New Ground in mCRC: Exploring Novel Targets in mCRC
MinuteCE®
Breaking New Ground in mCRC: Exploring Novel Targets in mCRC
- Scott Kopetz, MD, PhD
  Peer
- Cathy Eng, MD, FACP
  Peer
1.00 program credits
MinuteCE®
CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian Cancer
- Kathleen Moore, MD, MS
  Peer
- Joyce F. Liu, MD, MPH
  Peer
0.50 credits 5 episodes
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
MinuteCE®
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
- Joyce F. Liu, MD, MPH
  Peer
0.50 program credits
MOA: CDH6-Targeted Antibody-Drug Conjugates
MinuteCE®
MOA: CDH6-Targeted Antibody-Drug Conjugates
- Kathleen Moore, MD, MS
  Peer
0.50 program credits
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
MinuteCE®
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
- Joyce F. Liu, MD, MPH
  Peer
0.50 program credits
advertisement
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
MinuteCE®
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
- Kathleen Moore, MD, MS
  Peer
0.50 program credits
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
MinuteCE®
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
- Joyce F. Liu, MD, MPH
  Peer
- Kathleen Moore, MD, MS
  Peer
0.50 program credits
Advancing Clinical Expertise in CELMoDs: Transforming Multiple Myeloma Treatment
CME/CE
Advancing Clinical Expertise in CELMoDs: Transforming Multiple Myeloma Treatment
- Joshua Richter, MD
  Peer
1.00 credits

Program Chapters

Segment Chapters

Playlist:

Recommended